Efficacy of postoperative intraperitoneal hyperthermic perfusion chemotherapy with oxaliplatin+5-Fluorouracil in the treatment of gastric cancer patients with peritoneal carcinomatosis

被引:0
|
作者
Yan, Kangpeng [1 ]
Wu, Kun [1 ]
Yan, Lan [2 ]
Liang, Lei [3 ]
Yuan, Yujun [4 ]
机构
[1] Jiangxi Canc Hosp, Abdominal Surg Oncol Ward 1, 159 Beijing East Rd, Nanchang 330029, Jiangxi, Peoples R China
[2] Jiangxi Canc Hosp, Dept Radiol, Nanchang, Jiangxi, Peoples R China
[3] Tangshan Peoples Hosp, Dept Gastroenter Surg, Tangshan, Peoples R China
[4] Quannan Peoples Hosp Jiangxi Prov, Dept Gen Surg, Ganzhou, Peoples R China
来源
JOURNAL OF BUON | 2019年 / 24卷 / 04期
关键词
gastric cancer; peritoneal carcinomatosis; oxaliplatin; 5-fluorouracil; intraperitoneal hyperthermic perfusion chemotherapy; CYTOREDUCTIVE SURGERY; SURVIVAL; TUMORS; HIPEC;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To explore the effect of palliative laparoscopic resection of gastric cancer combined with intraperitoneal hyperthermic perfusion chemotherapy (IHPC) with oxaliplatin + 5-fluorouracil (5-FU) on gastric cancer patients with peritoneal carcinomatosis (PC). Methods: 90 patients definitely diagnosed with gastric adenocarcinoma and PC and admitted to our hospital from March 2013 to March 2016 were collected and divided into IHPC group (n=45) and control group (n=45). In IHPC group, IHPC with oxaliplatin + 5-FU was carried out for the first time on the first day after operation, and then it was conducted once every other day for a total of 4 times. The clinical efficacy, quality of life, adverse reactions, postoperative tumor recurrence and survival of the patients were observed and recorded. Results: The total effective rates in IHPC group and control group were 62.2% (28/45) and 55.6% (25/45), respectively (p>0.05). In both groups, the curative effect was the best in moderately differentiated adenocarcinoma and worst in signet ring cell carcinoma. Besides, the effective rates of Karnofsky performance status (KPS) in the two groups after operation were 82.2% (37/45) and 75.6% (34/45), respectively (p=0.606). However, the renal function indexes, serum creatinine (sCr) and blood urea nitrogen (BUN) in the two groups of patients after operation were increased, and those in the IHPC group were higher than those in the control group (p=0.016, p=0.010). Moreover, follow-up results of patients' survival revealed that the OS and PFS in the IHPC group were significantly higher than those in the control group (p=0.041, p=0.045). Conclusions: Palliative laparoscopic resection of gastric cancer combined with IHPC with oxaliplatin + 5-FU has a definite therapeutic effect on gastric cancer with PC, which can achieve a better short-term clinical therapeutic effect and better postoperative quality of life
引用
收藏
页码:1587 / 1594
页数:8
相关论文
共 50 条
  • [31] Current role of hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from colorectal cancer
    Rampone, Bernardino
    Schiavone, Beniamino
    Martino, Antonio
    Confuorto, Giuseppe
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (11) : 1299 - 1302
  • [32] Current role of hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from colorectal cancer
    Bernardino Rampone
    Beniamino Schiavone
    Antonio Martino
    Giuseppe Confuorto
    World Journal of Gastroenterology, 2010, 16 (11) : 1299 - 1302
  • [33] Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
    C. S. Chia
    B. You
    E. Decullier
    D. Vaudoyer
    G. Lorimier
    K. Abboud
    J.-M. Bereder
    C. Arvieux
    G. Boschetti
    O. Glehen
    Annals of Surgical Oncology, 2016, 23 : 1971 - 1979
  • [34] Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from gastric cancer
    Piso, P.
    Glockzin, G.
    Schlitt, H. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [35] Patients with Peritoneal Carcinomatosis from Gastric Cancer Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Is Cure a Possibility?
    Chia, C. S.
    You, B.
    Decullier, E.
    Vaudoyer, D.
    Lorimier, G.
    Abboud, K.
    Bereder, J. -M.
    Arvieux, C.
    Boschetti, G.
    Glehen, O.
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (06) : 1971 - 1979
  • [36] Iterative Intraperitoneal Chemotherapy in Gastric Cancer Peritoneal Carcinomatosis
    Tajik, Fatemeh
    Eyob, Belain
    Khan, Aaqil M.
    Radhakrishnan, Vinodh Kumar
    Senthil, Maheswari
    CANCERS, 2025, 17 (02)
  • [37] Cytoreduction and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis dissemination from colorectal cancer
    Turner, Keli
    Alexander, H. Richard, Jr.
    COLORECTAL CANCER, 2012, 1 (02) : 125 - 135
  • [38] Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis
    Detroz, B
    Laurent, S
    Honoré, P
    Blaffart, E
    Limet, R
    Meurisse, M
    ACTA CHIRURGICA BELGICA, 2004, 104 (04) : 377 - 383
  • [39] Comments on "Systemic exposure of oxaliplatin and docetaxel in gastric patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy"
    de Jong, Loek A. W.
    van Erp, Nielka P.
    de Reuver, Philip R.
    EJSO, 2021, 47 (05): : 1216 - 1217
  • [40] Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis
    Eric Marcotte
    Pierre Dubé
    Pierre Drolet
    Andrew Mitchell
    Suzanne Frenette
    Guy Leblanc
    Yves E Leclerc
    Lucas Sideris
    World Journal of Surgical Oncology, 12